In any case, our research indicates that MMP23B (Matrix Metalloproteinase 23B) is a potential therapeutic target for endometrial cancer, providing new ideas for the use of matrix metalloproteinase inhibitors in the treatment of endometrial cancer. Here, MMP23B is linked to endometrial cancer.